InvestorsObserver
×
News Home

Where Will Paratek Pharmaceuticals Inc (PRTK) Stock Go Next After It Has Fallen 9.80% in a Week?

Friday, April 22, 2022 10:51 AM | InvestorsObserver Analysts

Mentioned in this article

Where Will Paratek Pharmaceuticals Inc (PRTK) Stock Go Next After It Has Fallen 9.80% in a Week?

The market has been down on Paratek Pharmaceuticals Inc (PRTK) stock recently. PRTK gets a Bearish score from InvestorsObserver Stock Sentiment Indicator.

Sentiment Score - ,bearish
Paratek Pharmaceuticals Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on PRTK!

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With PRTK Stock Today?

Paratek Pharmaceuticals Inc (PRTK) stock is trading at $2.30 as of 10:50 AM on Friday, Apr 22, a loss of -$0.01, or -0.43% from the previous closing price of $2.31. The stock has traded between $2.29 and $2.38 so far today. Volume today is light. So far 137,322 shares have traded compared to average volume of 691,815 shares. To screen for more stocks like Paratek Pharmaceuticals Inc click here.

More About Paratek Pharmaceuticals Inc

Paratek Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's medical research is based on tetracycline chemistry and biology to create two antibacterials: omadacycline and sarecycline. NUZYRA (Omadacycline) is an antibacterial for skin infections and treatment of community-acquired bacterial pneumonia. SEYSARA (Sarecycline) is designed for use in the treatment of acne and rosacea. Paratek Pharmaceuticals is also involved in research to treat multiple sclerosis, spinal muscular atrophy, and systemic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel diseases. Click Here to get the full Stock Report for Paratek Pharmaceuticals Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App